Search

Learn about a heartburn-related condition called Barrett’s esophagus and its connection to a higher risk of esophageal cancer.

… Friday, July 10, 2020 Summary People with chronic heartburn may have gastroesophageal reflux disease . This can develop into a condition called Barrett’s esophagus , which increases the risk of esophageal cancer. Barrett’s esophagus should be closely monitored, and in some cases treated, to reduce this

Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.

… Tuesday, July 10, 2018 Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL) to inform disease management and predict survival and disease progression. However, recent research shows that among almost 1,500 patients with CLL who were treated in a community

By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.

… Thursday, May 12, 2022 Daniel Heller holding a model of a nanosensor Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK. Mijin Kim Kravis WiSE Postdoctoral Fellow Mijin Kim MSK surgeon Kara C. Long MSK surgeon Kara C. Long Lakshmi Ramanathan Lakshmi Ramanathan, Chief of

Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023.

… Monday, December 11, 2023 Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65 th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023. Highlights included essential insights into managing and reducing treatment-related

Learn about 14 students who will receive doctoral degrees from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at MSK.

… Tuesday, May 28, 2019 Summary This week 14 students will receive doctoral degrees from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at Memorial Sloan Kettering (MSK). They are the largest group to graduate in a given year since the school was established in 2004. The innovative program

… Sunday, September 30, 2007 This summer we witnessed young scientists at various crossroads in their careers. Our inaugural class of PhD students completed their first year of study and took the important step of choosing their thesis laboratories. We welcomed our second class of PhD students, who, at

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.

… Friday, April 1, 2011 Summary Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers. A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, “Where should I be treated?” Patients diagnosed with

Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

… Thursday, May 15, 2025 A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of life had reduced risk of developing a peanut allergy compared with children who avoided peanuts. Now, researchers at Memorial Sloan Kettering Cancer Center

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.

… Thursday, June 13, 2024 On June 13, 2024, a targeted drug called  repotrectinib (Augtyro TM ) received accelerated approval from the US Food and Drug Administration (FDA) for treating cancers caused by gene changes called  NTRK fusions. The clinical trial that resulted in the approval was led globally

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

… Thursday, May 19, 2011 A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center. The findings, which